Online citations, reference lists, and bibliographies.
← Back to Search

Analysis Of The Structural Basis Of Specificity Of Inhibition Of The Abl Kinase By STI571*

A. Corbin, E. Buchdunger, F. Pascal, B. Druker
Published 2002 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
STI571, a selective inhibitor of Bcr-Abl, has been a successful therapeutic agent in clinical trials for chronic myelogenous leukemia. Chronic phase chronic myelogenous leukemia patients treated with STI571 have durable responses; however, most responding blast phase patients relapse despite continued therapy. Co-crystallization studies of Abl kinase and an STI571-related compound identify specific amino acid residues as critical to STI571 binding, one of which, T315, has been characterized as an acquired Thr to Ile mutation in relapsed patients. Other studies, however, suggest that mutations other than these predicted contact points are capable of conferring STI571 resistance in relapsed patients. Using a variety of models of STI571 binding to the Abl kinase, we have performed an extensive mutational analysis of sites that might alter the sensitivity of the Abl kinase to STI571. Although mutation of many of the predicted contact points between Abl and STI571 result in a kinase-inactive protein, additional mutations that render the Abl kinase less sensitive to STI571 demonstrate a broad range of possibilities for clinical resistance that are now becoming evident.
This paper references
10.1056/NEJM200104053441402
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
B. Druker (2001)
10.1038/nm0596-561
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
B. Druker (1996)
10.1038/344251A0
Acute leukaemia in bcr/abl transgenic mice
N. Heisterkamp (1990)
10.1126/SCIENCE.2406902
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
G. Q. Daley (1990)
10.1126/SCIENCE.289.5486.1938
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
T. Schindler (2000)
10.1126/SCIENCE.276.5314.955
Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.
M. Mohammadi (1997)
10.1056/NEJM200104053441401
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
B. Druker (2001)
10.1126/SCIENCE.293.5538.2163A
Roots of clinical resistance to STI-571 cancer therapy.
C. Barthe (2001)
10.1038/384484A0
Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation
H. Yamaguchi (1996)
10.1126/SCIENCE.1062538
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
M. E. Gorre (2001)
10.1056/NEJM199904293401706
Chronic myeloid leukemia.
C. Sawyers (1999)
487–491 Specificity of Inhibition of the Abl Kinase by STI571
N. Engl (2001)
10.1016/S0140-6736(02)07679-1
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study
N. Bubnoff (2002)
10.7326/0003-4819-131-3-199908030-00008
Chronic Myelogenous Leukemia: Biology and Therapy
S. Faderl (1999)



This paper is referenced by
Synergistic Interactions between Imatinib and the Novel Phosphoinositide-Dependent Kinase-1 Inhibitor OSU-03012 in Overcoming Imatinib Resistance Running title : Overcome imatinib resistance by a PDK-1 inhibitor
P. Tseng (2005)
Mutants de domaines de la kinase de l'ABL
C. Barthe (2002)
10.1016/S0959-440X(02)00383-4
Protein tyrosine kinases: autoregulation and small-molecule inhibition.
S. Hubbard (2002)
10.1054/BLRE.2001.0152
Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?
M. Drummond (2001)
10.1038/sj.leu.2403831
An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate
T. Leguay (2005)
10.1182/BLOOD-2004-05-1851
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
T. O’Hare (2004)
ABL KINASE DOMAIN MUTATIONS AS A MECHANISM OF RESISTANCE TO TYROSINE KINASE INHIBITORS IN PHILADELPHIA-POSITIVE LEUKEMIAS: BIOLOGICAL, CLINICAL AND PROGNOSTIC RELEVANCE
(2007)
10.1002/cncr.23355
Molecular basis explanation for imatinib resistance of BCR‐ABL due to T315I and P‐loop mutations from molecular dynamics simulations
Tai-Sung Lee (2008)
10.6004/JNCCN.2005.0045
Resistance to imatinib: mechanisms and management.
M. Deininger (2005)
10.1007/978-1-59745-470-4_17
Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways
A. Reid (2008)
10.1038/tpj.2008.8
Somatic pharmacogenomics in cancer
O. Ikediobi (2008)
10.1158/0008-5472.CAN-05-0259
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
T. O’Hare (2005)
10.1038/sj.leu.2403775
Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies
C. Gambacorti-Passerini (2005)
Induced Cell Edge Translocation of Kinase-Active and Kinase-Defective Abl : Requirements of Myristoylation and SH 3 Domain
A. Fujita (2008)
10.1182/blood-2007-09-113860
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Anupriya Agarwal (2008)
domain mutations identify imatinib-treated patients with CML who have BCR-ABL kinase Real-time quantitative PCR analysis can be used as a primary screen to
Robin J Filshie (2012)
leukemia not contribute to tyrosine kinase inhibitor resistance in chronic myeloid insertion/truncation mutant is kinase-inactive and does 35INS The BCR-ABL
Michael W. Deininger (2012)
10.1038/sj.leu.2404137
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib
J. Khorashad (2006)
10.1182/BLOOD-2004-08-3097
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
M. Deininger (2005)
10.1111/J.1939-1676.2005.TB02778.X
A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats.
J. L. Lachowicz (2005)
10.1634/theoncologist.2010-0388
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
S. Soverini (2011)
10.1002/9781118098141.CH20
Drug Research Leading to Imatinib and beyond to Nilotinib
P. Manley (2012)
10.4161/cbt.319
Coadministration of UCN-01 with MEK1/2 Inhibitors Potently Induces Apoptosis in
C. Yu (2002)
10.4161/cc.9.18.13232
Allosteric inhibition of BCR-ABL
A. Q. Hassan (2010)
10.1385/1-59745-017-0:93
Detection of BCR-ABL mutations and resistance to imatinib mesylate.
S. Branford (2006)
10.1002/9781444327359.CH4
Diagnosis of Leukemias: New Diagnostic Modalities and Implications for Classification
Maher Albitar (2011)
Molecular Pharmacology Fast Forward
Selwyn S. Jayakar (2011)
10.1016/j.beha.2009.04.004
CML: a model for targeted therapy.
D. Cilloni (2009)
10.1586/14737140.8.1.99
Targeted therapy in chronic myeloid leukemia
E. Jabbour (2008)
Overcoming resistance to imatinib by combining targeted agents.
B. Druker (2003)
10.2174/1381612033454126
SRC family kinases: potential targets for the treatment of human cancer and leukemia.
M. Warmuth (2003)
10.1016/J.BIOPHA.2006.08.003
Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors.
M. Alaoui-Jamali (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar